Page 19 - Pharma Services News Today

NeoGenomics (NASDAQ:NEO – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of -$0.38–$0.32 for the period, compared to the consensus estimate of -$0.44. The company issued revenue guidance of $545.00 million-$555.00 million, compared to the consensus revenue estimate of $549.97 million. Analyst Upgrades and Downgrades […]

NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) has been given a consensus rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have issued a buy recommendation on the company. The […]

NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective trimmed by Bank of America from $18.00 to $17.00 in a research report report published on Tuesday, The Fly reports. The brokerage currently has a neutral rating on the medical research company’s stock. Other equities analysts have also issued research reports about the stock. Raymond James […]

The following Managements Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our audited consolidated financial... | April 12, 2023

NeoGenomics (NASDAQ:NEO – Get Rating) had its price target decreased by stock analysts at Bank of America from $18.00 to $17.00 in a research note issued on Tuesday, The Fly reports. Bank of America‘s price objective would indicate a potential upside of 11.48% from the stock’s previous close. Other equities analysts have also issued research […]

Needham & Company LLC restated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Get Rating) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $21.00 target price on the medical research company’s stock. Other research analysts have also recently issued research reports about the stock. Morgan Stanley raised […]

MetLife Investment Management LLC raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 1.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,436 shares of the medical research company’s stock after acquiring an additional 1,124 shares during the quarter. MetLife Investment Management […]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | April 5, 2023

Perkins Capital Management Inc. lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 197,700 shares of the medical research company’s stock after purchasing an additional 2,150 shares during the quarter. NeoGenomics […]

TORONTO, April 4, 2023 /CNW/ - Think Research Corporation ,  a company focused on transforming healthcare through digital health software solutions, is pleased to announce that today it has... | April 4, 2023